18B12

18B12 is a murine IgG2a monoclonal antibody that specifically targets the mouse CD20 antigen. It is widely utilized in preclinical research as a surrogate for clinical anti-CD20 therapies, such as rituximab, to study B-cell depletion and therapeutic strategies for B-cell malignancies in murine models (e.g., the Eμ-Tcl1 transgenic model of chronic lymphocytic leukemia). The antibody's primary mechanism of action is the depletion of CD20-positive B-cells through activatory Fcγ receptor-mediated processes, particularly antibody-dependent cellular phagocytosis (ADCP). In the context of the provided research, 18B12 was used to demonstrate that PI3Kδ inhibition enhances the efficacy and duration of anti-CD20 therapy by promoting Bim-dependent apoptosis.

Other names

anti-mouse CD20 antibody clone 18B12anti-CD20 mAb (18B12)